AbbVie Inc. Operating Income 2010-2024 | ABBV
AbbVie Inc. annual/quarterly operating income history and growth rate from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- AbbVie Inc. operating income for the quarter ending December 31, 2024 was $-1.490B, a 146.64% decline year-over-year.
- AbbVie Inc. operating income for the twelve months ending December 31, 2024 was $9.137B, a 28.38% decline year-over-year.
- AbbVie Inc. annual operating income for 2024 was $9.137B, a 28.38% decline from 2023.
- AbbVie Inc. annual operating income for 2023 was $12.757B, a 29.59% decline from 2022.
- AbbVie Inc. annual operating income for 2022 was $18.117B, a 1.08% increase from 2021.
AbbVie Inc. Annual Operating Income
(Millions of US $) |
| 2024 |
$9,137 |
| 2023 |
$12,757 |
| 2022 |
$18,117 |
| 2021 |
$17,924 |
| 2020 |
$11,363 |
| 2019 |
$12,983 |
| 2018 |
$6,383 |
| 2017 |
$9,545 |
| 2016 |
$9,340 |
| 2015 |
$7,537 |
| 2014 |
$3,411 |
| 2013 |
$5,664 |
| 2012 |
$5,817 |
| 2011 |
$3,620 |
| 2010 |
$4,717 |
| 2009 |
$4,932 |
AbbVie Inc. Quarterly Operating Income
(Millions of US $) |
| 2024-12-31 |
$-1,490 |
| 2024-09-30 |
$3,831 |
| 2024-06-30 |
$3,998 |
| 2024-03-31 |
$2,798 |
| 2023-12-31 |
$3,195 |
| 2023-09-30 |
$2,281 |
| 2023-06-30 |
$4,513 |
| 2023-03-31 |
$2,768 |
| 2022-12-31 |
$5,502 |
| 2022-09-30 |
$4,603 |
| 2022-06-30 |
$3,295 |
| 2022-03-31 |
$4,717 |
| 2021-12-31 |
$5,074 |
| 2021-09-30 |
$4,306 |
| 2021-06-30 |
$4,441 |
| 2021-03-31 |
$4,103 |
| 2020-12-31 |
$3,753 |
| 2020-09-30 |
$3,255 |
| 2020-06-30 |
$752 |
| 2020-03-31 |
$3,603 |
| 2019-12-31 |
$3,956 |
| 2019-09-30 |
$2,617 |
| 2019-06-30 |
$3,400 |
| 2019-03-31 |
$3,010 |
| 2018-12-31 |
$-2,441 |
| 2018-09-30 |
$3,159 |
| 2018-06-30 |
$2,762 |
| 2018-03-31 |
$2,903 |
| 2017-12-31 |
$1,782 |
| 2017-09-30 |
$2,694 |
| 2017-06-30 |
$2,662 |
| 2017-03-31 |
$2,407 |
| 2016-12-31 |
$2,314 |
| 2016-09-30 |
$2,361 |
| 2016-06-30 |
$2,387 |
| 2016-03-31 |
$2,278 |
| 2015-12-31 |
$2,113 |
| 2015-09-30 |
$1,885 |
| 2015-06-30 |
$1,852 |
| 2015-03-31 |
$1,687 |
| 2014-12-31 |
$-415 |
| 2014-09-30 |
$960 |
| 2014-06-30 |
$1,515 |
| 2014-03-31 |
$1,351 |
| 2013-12-31 |
$1,535 |
| 2013-09-30 |
$1,371 |
| 2013-06-30 |
$1,453 |
| 2013-03-31 |
$1,305 |
| 2012-12-31 |
$1,821 |
| 2012-09-30 |
$1,596 |
| 2012-06-30 |
$1,422 |
| 2012-03-31 |
$978 |
| 2011-12-31 |
$-5,887 |
| 2011-09-30 |
$4,409 |
| 2011-06-30 |
$4,274 |
| 2011-03-31 |
$824 |
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$356.743B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
